TuHURA Biosciences (HURA) Price & Analysis

Compare

953 Followers

HURA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.80 - $8.36

Previous CloseN/A

Volume116.05K

Average Volume (3M)592.81K

Market Cap

$127.62M

Enterprise Value$91.68M

Total Cash (Recent Filing)$8.51M

Total Debt (Recent Filing)$558.97K

Price to Earnings (P/E)―

Beta-0.37

Next Earnings

Sep 30, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding50,046,925

10 Day Avg. Volume244,783

30 Day Avg. Volume592,810

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.72

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-5.20K

Enterprise Value/Ebitda-5.34

Forecast

1Y Price Target

$12.00

Price Target Upside370.59% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe initiation of the Phase 3 accelerated approval trial of IFx-2.0 in patients with advanced or metastatic Merkel cell carcinoma is a significant step forward for Tuhura Biosciences.

Financial PositionTuhura Biosciences announced it entered into an equity financing that should bring in an aggregate $12.5M in capital, combined with $3M raised from warrant exercises and $12.4M in cash, providing financial runway into the first half of 2026.

Mergers And AcquisitionsThe acquisition with Kineta completed in June brings on board the anti-VISTA checkpoint inhibitor (CPI), now called TBS-2025, marking a significant milestone for TuHURA.

Bears Say

Financial PerformanceTuHURA Biosciences reported a net loss of $0.21 per share—wider than previously estimated.

Market CompetitionThere are competitive risks, especially with respect to other checkpoint inhibitors, which could impact Tuhura Biosciences' market position.

Operational RisksRisks include negative clinical results with IFx-2.0 and delays in advancing pipeline candidates into registrational programs.

TuHURA Biosciences News

TuHURA Biosciences files to sell 4.76M shares of common stock for holders

16:35 EDT TuHURA Biosciences (HURA) files to sell 4.76M shares of common stock for holders Published first on...

26d ago

HURA

Buy Rating on TuHURA Biosciences: Strategic Financial Projections and Upcoming Catalysts Drive Growth Potential

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on HURA stock, giving a Buy rating on...

17d ago

HURA

TuHURA Biosciences Advances Clinical Trials and Strengthens Market Position

TuHURA Biosciences ( ($HURA) ) has issued an announcement. TuHURA Biosciences has announced significant advancements in its clinical...

24d ago

HURA

TuHURA Biosciences included in Russell 3000 and 2000 Indexes

TuHURA Biosciences (HURA) has been added to the Russell 3000 Index, with automatic inclusion in the Russell 2000...

2M ago

HURA

TuHURA Biosciences Completes Acquisition of Kineta, Inc.

TuHURA Biosciences ( ($HURA) ) has shared an announcement. On June 30, 2025, TuHURA Biosciences completed its acquisition...

2M ago

HURA

TuHURA Biosciences Increases Authorized Common Stock Shares

An announcement from TuHURA Biosciences ( ($HURA) ) is now available. On June 23, 2025, TuHURA Biosciences‘ stockholders...

2M ago

HURA

Buy Rating for TuHURA Biosciences: Promising Phase 3 Study and Strategic Merger with Kineta Inc.

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on TuHURA Biosciences (HURA – Research Report), retaining...

2M ago

HURA

TuHURA Biosciences initiates Phase 3 approval trial of IFx-2.0 in carcinoma

TuHURA Biosciences (HURA) initiated its Phase 3 accelerated approval trial of IFx-2.0, TuHURA’s lead innate immune agonist, in...

3M ago

HURA

TuHURA Biosciences Approves Merger and Share Increase

TuHURA Biosciences ( ($HURA) ) has provided an update. On June 23, 2025, TuHURA Biosciences held a Special...

3M ago

HURA

TuHURA Biosciences, Kineta stockholders approve merger and related proposals

TuHURA Biosciences (HURA) announced with Kineta (KANT) that TuHURA stockholders approved all of the proposals set forth at...

3M ago

HURA

KANT

TuHURA Biosciences initiated with a Buy at Brookline

Brookline initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $9 price target TuHURA Biosciences is...

3M ago

HURA

TuHURA Biosciences Approves Executive Salary Increases

TuHURA Biosciences ( ($HURA) ) has shared an update. On June 6, 2025, TuHURA Biosciences‘ Compensation Committee approved...

3M ago

HURA

TuHURA announces FDA removed partial clinical hold on Phase 3 trial of IFx-2.0

TuHURA Biosciences (HURA) announced that the FDA has removed the manufacturing-related partial clinical hold on the Company’s Phase...

3M ago

HURA

TuHURA Biosciences Secures $12.6M for Strategic Initiatives

TuHURA Biosciences ( ($HURA) ) has shared an update. On June 2, 2025, TuHURA Biosciences announced a $12.6...

3M ago

HURA

HURA FAQ

What was TuHURA Biosciences’s price range in the past 12 months?

TuHURA Biosciences lowest stock price was $1.80 and its highest was $8.36 in the past 12 months.

What is TuHURA Biosciences’s market cap?

TuHURA Biosciences’s market cap is $127.62M.

When is TuHURA Biosciences’s upcoming earnings report date?

TuHURA Biosciences’s upcoming earnings report date is Sep 30, 2025 which is in 22 days.

How were TuHURA Biosciences’s earnings last quarter?

TuHURA Biosciences released its earnings results on Aug 14, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.16 by -$0.05.

Is TuHURA Biosciences overvalued?

According to Wall Street analysts TuHURA Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does TuHURA Biosciences pay dividends?

TuHURA Biosciences does not currently pay dividends.

What is TuHURA Biosciences’s EPS estimate?

TuHURA Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does TuHURA Biosciences have?

TuHURA Biosciences has 50,046,925 shares outstanding.

What happened to TuHURA Biosciences’s price movement after its last earnings report?

TuHURA Biosciences reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.16. Following the earnings report the stock price went up 10.87%.

Which hedge fund is a major shareholder of TuHURA Biosciences?

Currently, no hedge funds are holding shares in HURA

TuHURA Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-287.92%

Trailing 12-Months

Asset Growth

1736.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

TuHURA Biosciences

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

TuHURA Biosciences (HURA) Earnings & Revenues

Historic Earnings Reports

HURA Stock 12 Month Forecast

Average Price Target

$12.00

▲(370.59% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","132":"$132","263":"$263","66.5":"$66.5","197.5":"$197.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,66.5,132,197.5,263],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.4,3.3692307692307693,4.338461538461538,5.3076923076923075,6.276923076923077,7.246153846153845,8.215384615384615,9.184615384615384,10.153846153846153,11.123076923076923,12.092307692307692,13.061538461538461,14.03076923076923,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.4,3.1384615384615384,3.8769230769230765,4.615384615384615,5.3538461538461535,6.092307692307692,6.83076923076923,7.569230769230769,8.307692307692307,9.046153846153846,9.784615384615384,10.523076923076923,11.26153846153846,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.4,2.9076923076923076,3.4153846153846152,3.923076923076923,4.430769230769231,4.938461538461539,5.446153846153846,5.953846153846154,6.461538461538462,6.969230769230769,7.476923076923077,7.984615384615385,8.492307692307692,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":262.15,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.65,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.6,"date":1675209600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":141.05,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.62,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.41,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >